Article PDF
Rights and permissions
About this article
Cite this article
Vasey, P., Kaye, S. Combined inhibition of topoisomerases I and II - is this a worthwhile/feasible strategy?. Br J Cancer 76, 1395–1397 (1997). https://doi.org/10.1038/bjc.1997.568
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.568
This article is cited by
-
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer
Cancer Chemotherapy and Pharmacology (2012)
-
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer
Cancer Chemotherapy and Pharmacology (2007)
-
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
British Journal of Cancer (2004)
-
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
British Journal of Cancer (2003)
-
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
British Journal of Cancer (2003)